Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## **HUA MEDICINE**

## 華領醫藥

(Incorporated in the Cayman Islands with limited liability)
(stock code: 2552)

## VOLUNTARY ANNOUNCEMENT IND APPLICATION OF 2<sup>nd</sup> GENERATION GLUCOKINASE ALLOSTERIC ACTIVATOR FILED WITH AND ACCEPTED BY FDA

This is a voluntary announcement made by Hua Medicine (the "Company", together with its subsidiaries, the "Group") to provide its shareholders and potential investors with information in relation to the latest business update of the Company.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for the 2<sup>nd</sup> generation glucokinase allosteric activator (2<sup>nd</sup> Gen GKA) to initiate a Phase 1 randomized, double-blinded, placebo-controlled, single-dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study in subjects with Type 2 diabetes mellitus (T2D) in the United States.

This IND filing is the first step in the Company's strategy to expand its innovative approach of "repairing the sensor, restoring homeostasis, and treating the underlying cause of diabetes" beyond mainland China, where its first-generation GKA is approved and has been successfully commercialized for the treatment of Type 2 diabetes. The 2<sup>nd</sup> Gen GKA is a new molecular entity with improved physical-chemical properties and formulated using the Company's proprietary formulation platform for once daily oral administration. The Company retains all global proprietary rights to its 2<sup>nd</sup> Gen GKA.

The 2<sup>nd</sup> Gen GKA was designed as an extended release formulation to allow for once daily administration for added convenience for patients, as well as increasing the duration of the drug in the intestinal organs leading to the enhanced repair of deficient GLP-1 secretion in patients. We believe that in combination with existing approved therapeutics, our GKA candidates have the potential to achieve effective glycemic control over a continuous 24-hour period. Specifically, we believe our GKA candidates offers the potential for huge synergies in combination with GLP-1 therapeutics especially in those patients with high fluctuations in glucose levels.

Upon successful completion of the Phase I study, the Company intends to seek partners to develop the  $2^{nd}$  Gen GKA for the global markets.

Cautionary Statement required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, 2<sup>nd</sup> Gen GKA successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board

Hua Medicine

Dr. Li Chen

Chief Executive Officer and Executive Director

Shanghai, 21 December 2023

As at the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Dr. Fangxin LI as non-executive Directors; and Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung as independent non-executive Directors.